Recommendations for managing Aspergillus osteomyelitis and joint infections based on a review of the literature

被引:30
作者
Kirby, Andrew
Hassan, Ibrahim
Burnie, James
机构
[1] Manchester Royal Infirm, Dept Microbiol, Manchester M13 9WL, Lancs, England
[2] Manchester Royal Infirm, NeutecPharma PLC, Manchester M13 9WL, Lancs, England
关键词
Aspergillus; osteomyelitis; anti-fungal pharmacology;
D O I
10.1016/j.jinf.2005.08.016
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To produce recommendations for the management of Aspergillus osteomyelitis and joint infections. Methods: Published literature was surveyed to identify both case reports of Aspergillus osteomyelitis and joint infections and anti-fungal pharmacology of anti-fungal agents. Included in the pharmacological review was an assessment of new and investigational anti-fungals to consider their potential role in the management of this infection. Results: Successful treatments, identified from the cases reviewed, were based on combination anti-fungal therapy with one agent having good bone penetration and one having reliable anti-Aspergillus activity. Conclusions: For the management of serious Aspergillus osteomyleitis/joint infections amphotericin B in combination with flucytosine is recommended. A number. of second Line treatment combinations are identified. Monotherapy is appropriate with an azole in clinically stable patients. (C) 2006 The British Infection Society. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:405 / 414
页数:10
相关论文
共 102 条
[71]   Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole [J].
Oakley, KL ;
Moore, CB ;
Denning, DW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1264-1266
[72]   In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. [J].
Perea, S ;
Gonzalez, G ;
Fothergill, AW ;
Kirkpatrick, WR ;
Rinaldi, MG ;
Patterson, TF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (09) :3039-3041
[73]   Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi:: Report from SENTRY Antimicrobial Surveillance Program, 2000 [J].
Pfaller, MA ;
Messer, SA ;
Hollis, RJ ;
Jones, RN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) :1032-1037
[74]   PHARMACOKINETICS OF AMPHOTERICIN-B AND FLUCYTOSINE [J].
POLAK, A .
POSTGRADUATE MEDICAL JOURNAL, 1979, 55 (647) :667-670
[75]   Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety [J].
Purkins, L ;
Wood, N ;
Greenhalgh, K ;
Allen, MJ ;
Oliver, SD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 :10-16
[76]   The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent [J].
Purkins, L ;
Wood, N ;
Greenhalgh, K ;
Eve, MD ;
Oliver, SD ;
Nichols, D .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 :2-9
[77]  
Rajaram T, 1991, J Neurosurg Sci, V35, P117
[78]   A CASE OF ASPERGILLUS OSTEOMYELITIS COMPLICATING AN OPEN FRACTURE OF THE TIBIA [J].
RICHARDS, RH ;
PRIAULX, LR .
INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED, 1988, 19 (02) :129-130
[79]   ASPERGILLUS FLAVIPES GROUP OSTEOMYELITIS [J].
ROSELLE, GA ;
BAIRD, IM .
ARCHIVES OF INTERNAL MEDICINE, 1979, 139 (05) :590-592
[80]   AMPHOTERICIN-RESISTANT ASPERGILLUS OSTEOMYELITIS CONTROLLED BY ITRACONAZOLE [J].
SACHS, MK ;
PALUZZI, RG ;
MOORE, JH ;
FRAIMOW, HS ;
OST, D .
LANCET, 1990, 335 (8703) :1475-1475